DNAJA1: Key Regulator of The Cytoskeleton and Potential Drug/Biomarker

Target Name: DNAJA1

NCBI ID: G3301

DNAJA1

DNAJA1: Key Regulator of The Cytoskeleton and Potential Drug/Biomarker

DNAJA1 (also known as HDJ2) is a protein that is expressed in most tissues of the body. It is a key regulator of the cytoskeleton, which is the structure that gives shape to the cells. There are several different forms of DNAJA1, each of which is expressed in different tissues at different levels.

One of the forms of DNAJA1 is a protein that is expressed in the brain. This form of the protein is called brain-specific DNAJA1 (BSDNAJA1) and it is expressed at higher levels in the brain than in other tissues. BSDNAJA1 is involved in the formation and maintenance of the cytoskeleton in the brain, which is important for the proper functioning of the brain cells.

Another form of DNAJA1 is a protein that is expressed in the heart. This form of the protein is called heart-specific DNAJA1 (HSDNAJA1) and it is expressed at higher levels in the heart than in other tissues. HSDNAJA1 is involved in the formation and maintenance of the cytoskeleton in the heart, which is important for the proper functioning of the heart cells.

In addition to its role in the cytoskeleton, DNAJA1 is also involved in the regulation of cell signaling pathways. It is a component of several signaling pathways that are important for the growth, development, and survival of cells. For example, DNAJA1 is a key regulator of the PI3K/Akt signaling pathway, which is involved in the signaling pathways that are important for the growth and survival of cancer cells.

DNAJA1 is also a potential drug target. There are several studies that have suggested that DNAJA1 may be a useful target for the treatment of various diseases, including cancer. For example, several studies have shown that inhibiting the activity of DNAJA1 has the potential to be a effective way to treat cancer by inhibiting the growth and survival of cancer cells.

In addition to its potential as a drug target, DNAJA1 is also a potential biomarker. There are several studies that have suggested that DNAJA1 may be a useful biomarker for the diagnosis and prognosis of various diseases, including cancer. For example, several studies have shown that the level of DNAJA1 in a patient's blood is often elevated when the patient has cancer, which suggests that DNAJA1 may be a useful biomarker for the diagnosis of cancer.

Overall, DNAJA1 is a protein that is expressed in most tissues of the body and is involved in the formation and maintenance of the cytoskeleton. It is also involved in the regulation of cell signaling pathways and is a potential drug target and biomarker. Further research is needed to fully understand the role of DNAJA1 in the body and its potential as a drug and biomarker.

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member A1

Functions: Co-chaperone for HSPA8/Hsc70 (PubMed:10816573). Stimulates ATP hydrolysis, but not the folding of unfolded proteins mediated by HSPA1A (in vitro) (PubMed:24318877). Plays a role in protein transport into mitochondria via its role as co-chaperone. Functions as co-chaperone for HSPA1B and negatively regulates the translocation of BAX from the cytosol to mitochondria in response to cellular stress, thereby protecting cells against apoptosis (PubMed:14752510). Promotes apoptosis in response to cellular stress mediated by exposure to anisomycin or UV (PubMed:24512202)

The "DNAJA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets